FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101331380> ?p ?o ?g. }

• W2101331380 endingPage "784" @default.
• W2101331380 startingPage "775" @default.
• W2101331380 abstract "Safety and efficacy of quinupristin-dalfopristin (an injectable streptogramin antibiotic) were evaluated in the treatment of a variety of infections due to methicillin-resistant Staphylococcus aureus (MRSA) in patients either intolerant of or failing prior therapy. The influence of resistance phenotypes on treatment outcome was also assessed. This worldwide, multicentre, open-label, non-comparative, emergency-use clinical study enrolled patients with one or more of nine predefined, culture-confirmed infections with MRSA, who had no clinically appropriate alternative antibiotic therapy. The recommended quinupristin-dalfopristin dose was 7.5 mg/kg administered iv every 8 h for a duration judged appropriate by the investigator. There were no restrictions on prior or concomitant treatment with other antibiotics. Clinical, microbiological and laboratory assessments were performed at baseline, during study drug treatment, within 24 h after the last dose, and 7-21 days post-therapy. Ninety patients [age (mean +/- S.D.) 57.4 +/- 18.5 years] with significant underlying medical illnesses were treated at 63 centres in five countries. The most common indications were bone and joint infection (44.4% of patients) and skin and skin structure infection (16.7%). The mean (+/- S.D.) daily dose and treatment duration was 20.2 +/- 2.9 mg/kg/day for 28.5 +/- 22.3 days, most frequently administered every 8 h. The overall success rate (defined as a clinical outcome of either cure or improvement and a bacteriological outcome of eradication or presumed eradication) was 71.1% in the all-treated population (n = 90) and 66.7% in patients who were both clinically and bacteriologically evaluable (n = 27). Success rates for endocarditis, respiratory tract infection and bacteraemia of unknown source were below the population mean. The macrolide-lincosamide-streptogramin type B resistance phenotype did not appear to alter the response rate. The most common non-venous adverse events related to study medication were arthralgias (10.8%), myalgias (8.6%) and nausea (8.6%). Quinupristin-dalfopristin should be considered as a treatment option for infections caused by MRSA, especially in patients intolerant of or failing alternate therapy." @default.
• W2101331380 created "2016-06-24" @default.
• W2101331380 creator A5028777325 @default.
• W2101331380 creator A5040064051 @default.
• W2101331380 creator A5042995773 @default.
• W2101331380 creator A5050990294 @default.
• W2101331380 creator A5080609948 @default.
• W2101331380 creator A5082800922 @default.
• W2101331380 date "2000-11-01" @default.
• W2101331380 modified "2023-10-16" @default.
• W2101331380 title "Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy" @default.
• W2101331380 cites W1985250743 @default.
• W2101331380 cites W1989526018 @default.
• W2101331380 cites W1992819072 @default.
• W2101331380 cites W1998272040 @default.
• W2101331380 cites W2006392489 @default.
• W2101331380 cites W2008494176 @default.
• W2101331380 cites W2033260007 @default.
• W2101331380 cites W2047649930 @default.
• W2101331380 cites W2097083775 @default.
• W2101331380 cites W2102278891 @default.
• W2101331380 cites W2106935542 @default.
• W2101331380 cites W2113416495 @default.
• W2101331380 cites W2119452872 @default.
• W2101331380 cites W2127268315 @default.
• W2101331380 cites W2130824573 @default.
• W2101331380 cites W2137119107 @default.
• W2101331380 cites W2147597284 @default.
• W2101331380 cites W2151417429 @default.
• W2101331380 cites W2157620025 @default.
• W2101331380 cites W2159145150 @default.
• W2101331380 cites W2160104373 @default.
• W2101331380 cites W2160549172 @default.
• W2101331380 cites W2166869546 @default.
• W2101331380 cites W2167337159 @default.
• W2101331380 cites W2187292340 @default.
• W2101331380 cites W2314688271 @default.
• W2101331380 cites W2322877860 @default.
• W2101331380 cites W2329427515 @default.
• W2101331380 cites W2417598117 @default.
• W2101331380 cites W2144005980 @default.
• W2101331380 doi "https://doi.org/10.1093/jac/46.5.775" @default.
• W2101331380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11062197" @default.
• W2101331380 hasPublicationYear "2000" @default.
• W2101331380 type Work @default.
• W2101331380 sameAs 2101331380 @default.
• W2101331380 citedByCount "150" @default.
• W2101331380 countsByYear W21013313802012 @default.
• W2101331380 countsByYear W21013313802013 @default.
• W2101331380 countsByYear W21013313802014 @default.
• W2101331380 countsByYear W21013313802015 @default.
• W2101331380 countsByYear W21013313802016 @default.
• W2101331380 countsByYear W21013313802017 @default.
• W2101331380 countsByYear W21013313802018 @default.
• W2101331380 countsByYear W21013313802019 @default.
• W2101331380 countsByYear W21013313802020 @default.
• W2101331380 countsByYear W21013313802021 @default.
• W2101331380 countsByYear W21013313802022 @default.
• W2101331380 crossrefType "journal-article" @default.
• W2101331380 hasAuthorship W2101331380A5028777325 @default.
• W2101331380 hasAuthorship W2101331380A5040064051 @default.
• W2101331380 hasAuthorship W2101331380A5042995773 @default.
• W2101331380 hasAuthorship W2101331380A5050990294 @default.
• W2101331380 hasAuthorship W2101331380A5080609948 @default.
• W2101331380 hasAuthorship W2101331380A5082800922 @default.
• W2101331380 hasBestOaLocation W21013313801 @default.
• W2101331380 hasConcept C126322002 @default.
• W2101331380 hasConcept C141071460 @default.
• W2101331380 hasConcept C2777052132 @default.
• W2101331380 hasConcept C2777874012 @default.
• W2101331380 hasConcept C2778980435 @default.
• W2101331380 hasConcept C2779384505 @default.
• W2101331380 hasConcept C2779489039 @default.
• W2101331380 hasConcept C2780944852 @default.
• W2101331380 hasConcept C2908647359 @default.
• W2101331380 hasConcept C3019249092 @default.
• W2101331380 hasConcept C501593827 @default.
• W2101331380 hasConcept C523546767 @default.
• W2101331380 hasConcept C54355233 @default.
• W2101331380 hasConcept C71924100 @default.
• W2101331380 hasConcept C86803240 @default.
• W2101331380 hasConcept C89423630 @default.
• W2101331380 hasConcept C99454951 @default.
• W2101331380 hasConceptScore W2101331380C126322002 @default.
• W2101331380 hasConceptScore W2101331380C141071460 @default.
• W2101331380 hasConceptScore W2101331380C2777052132 @default.
• W2101331380 hasConceptScore W2101331380C2777874012 @default.
• W2101331380 hasConceptScore W2101331380C2778980435 @default.
• W2101331380 hasConceptScore W2101331380C2779384505 @default.
• W2101331380 hasConceptScore W2101331380C2779489039 @default.
• W2101331380 hasConceptScore W2101331380C2780944852 @default.
• W2101331380 hasConceptScore W2101331380C2908647359 @default.
• W2101331380 hasConceptScore W2101331380C3019249092 @default.
• W2101331380 hasConceptScore W2101331380C501593827 @default.
• W2101331380 hasConceptScore W2101331380C523546767 @default.
• W2101331380 hasConceptScore W2101331380C54355233 @default.
• W2101331380 hasConceptScore W2101331380C71924100 @default.
• W2101331380 hasConceptScore W2101331380C86803240 @default.

• next